The one-two punch (of CAR T cells)

Abstract

In this issue of Blood, Pan et al highlight their approach toward dual-antigen chimeric antigen receptor (CAR) T-cell targeting in an effort to reduce the risk of immune escape in pediatric B-cell acute lymphoblastic leukemia (B-ALL). They demonstrate the feasibility of sequentially administering CD19 CAR T cells followed by CD22 CAR T cells alongside the safety, toxicity, and efficacy of such a model. Their observation suggests that sequential CAR T-cell targeting strategies may be safe and effective and provides proof-of-concept of a potential strategy that may allow for dual-antigen CAR T-cell targeting.